| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Celso Arango, Daisy Ng-Mak, Elaine Finn, Aidan Byrne, Antony Loebe. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. European child & adolescent psychiatry. vol 29. issue 9. 2020-10-13. PMID:31758359. |
lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. |
2020-10-13 |
2023-08-13 |
Not clear |
| Celso Arango, Daisy Ng-Mak, Elaine Finn, Aidan Byrne, Antony Loebe. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. European child & adolescent psychiatry. vol 29. issue 9. 2020-10-13. PMID:31758359. |
this network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. |
2020-10-13 |
2023-08-13 |
Not clear |
| Philip D Harvey, Cynthia O Siu, Antony D Loebe. Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia. Schizophrenia research. Cognition. vol 5. 2020-09-30. PMID:28740811. |
change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine xr in patients with schizophrenia. |
2020-09-30 |
2023-08-13 |
human |
| Jonathan M Meyer, Daisy S Ng-Mak, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebe. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Annals of general psychiatry. vol 16. 2020-09-30. PMID:29075309. |
this analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder. |
2020-09-30 |
2023-08-13 |
Not clear |
| Mohammad Rafi, Chhaya Goyal, Pooja Reddy, Shrikanth Redd. Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression? Indian journal of psychological medicine. vol 40. issue 2. 2020-09-28. PMID:29962579. |
the u.s. food and drug administration (fda) has approved a supplemental new drug application lurasidone (latuda, sunovion pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13-17 years of age. |
2020-09-28 |
2023-08-13 |
Not clear |
| Mohammad Rafi, Chhaya Goyal, Pooja Reddy, Shrikanth Redd. Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression? Indian journal of psychological medicine. vol 40. issue 2. 2020-09-28. PMID:29962579. |
lurasidone was previously indicated in the u.s. for the treatment of adults with schizophrenia and major depressive episodes with bipolar i disorder as monotherapy. |
2020-09-28 |
2023-08-13 |
Not clear |
| Daisy Ng-Mak, Andrew Messali, Ahong Huang, Li Wang, Antony Loebe. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. The American journal of managed care. vol 25. issue 14 Suppl. 2020-09-23. PMID:31365818. |
this study compared the risk of hospitalization among adults with schizophrenia being treated with equivalent dose ranges of lurasidone versus aripiprazole, olanzapine, quetiapine, or risperidone. |
2020-09-23 |
2023-08-13 |
Not clear |
| Daisy Ng-Mak, Andrew Messali, Ahong Huang, Li Wang, Antony Loebe. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. The American journal of managed care. vol 25. issue 14 Suppl. 2020-09-23. PMID:31365818. |
as hospitalization is a major cost driver of direct healthcare cost, lurasidone may be a cost-saving treatment option for patients with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Monalisa Jena, Rajeev Ranjan, Biswa Ranjan Mishra, Archana Mishra, Santanu Nath, Pallabi Sahu, Bikash Ranjan Meher, Anand Srinivasan, Rituparna Mait. Corrigendum to "Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial" [J. Psychiatr. Res. 112 (2019) 1-6]. Journal of psychiatric research. vol 126. 2020-09-17. PMID:31831143. |
corrigendum to "effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: a randomized controlled trial" [j. psychiatr. |
2020-09-17 |
2023-08-13 |
Not clear |
| S K Zyryanov, I N Dyakov, A A Juperin, D A Egorova, E S Mosolov. [The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 120. issue 6. Vyp. 2. 2020-09-17. PMID:32729695. |
[the pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia]. |
2020-09-17 |
2023-08-13 |
Not clear |
| S K Zyryanov, I N Dyakov, A A Juperin, D A Egorova, E S Mosolov. [The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 120. issue 6. Vyp. 2. 2020-09-17. PMID:32729695. |
to conduct a comprehensive pharmacoeconomic evaluation of lurasidone for the treatment of patients with schizophrenia under russian healthcare system conditions and inclusion in edl (essential drugs list) and medication list for the certain categories of citizens. |
2020-09-17 |
2023-08-13 |
Not clear |
| Filippo Corponi, Chiara Fabbri, Istvan Bitter, Stuart Montgomery, Eduard Vieta, Siegfried Kasper, Stefano Pallanti, Alessandro Serrett. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 9. 2020-08-07. PMID:31255396. |
as the number of sgas increased, this review can assist physicians in the prescription of three novel sgas already on the market, namely lurasidone, brexpiprazole, cariprazine, and lumateperone, which is in the approval phase for schizophrenia treatment at the fda. |
2020-08-07 |
2023-08-13 |
Not clear |
| Monalisa Jena, Rajeev Ranjan, Biswa Ranjan Mishra, Archana Mishra, Santanu Nath, Pallabi Sahu, Bikash Ranjan Meher, Anand Srinivasan, Rituparna Mait. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. Journal of psychiatric research. vol 112. 2020-06-22. PMID:30782512. |
effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: a randomized controlled trial. |
2020-06-22 |
2023-08-13 |
Not clear |
| Monalisa Jena, Rajeev Ranjan, Biswa Ranjan Mishra, Archana Mishra, Santanu Nath, Pallabi Sahu, Bikash Ranjan Meher, Anand Srinivasan, Rituparna Mait. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. Journal of psychiatric research. vol 112. 2020-06-22. PMID:30782512. |
the objective of the present study was to investigate and compare the effect of olanzapine and lurasidone on the change in serum neurotrophins in patients with schizophrenia. |
2020-06-22 |
2023-08-13 |
Not clear |
| Heather Burrell Ward, Benjamin L Yudkoff, John A Fromso. Lurasidone Malabsorption Following Bariatric Surgery: A Case Report. Journal of psychiatric practice. vol 25. issue 4. 2020-06-19. PMID:31291214. |
lurasidone, a second-generation antipsychotic used to treat schizophrenia and bipolar disorder, is recommended to be taken with food of at least 350 calories. |
2020-06-19 |
2023-08-13 |
Not clear |
| Vivek C Kirpekar, Abhijeet D Faye, Sudhir H Bhave, Rahul Tadke, Sushil Gawand. Lurasidone-induced anemia: Is there a need for hematological monitoring? Indian journal of pharmacology. vol 51. issue 4. 2020-03-13. PMID:31571715. |
lurasidone is a newer drug used for treating schizophrenia and depression in bipolar disorder. |
2020-03-13 |
2023-08-13 |
Not clear |
| S N Mosolov, A V Malyutin, A A Pikalo. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 119. issue 12. 2020-01-31. PMID:31994511. |
[effect of lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from russia and ukraine]. |
2020-01-31 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Masaomi Iyo, Jun Soo Kwon, Yuan-Hwa Chou, Hsing-Kang Chen, Jen-Yeu Chen, Tzu-Ting Chen, San-Yuan Huang, Jung-Sik Lee, Yuichi Saeki, Hisashi Tanaka, Tzong-Shi Wang, Bo-Jian Wu, Takao Katoh, Jun Ishigouok. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 11. issue 3. 2020-01-28. PMID:30912222. |
randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: results of an inconclusive 6-week trial. |
2020-01-28 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Masaomi Iyo, Jun Soo Kwon, Yuan-Hwa Chou, Hsing-Kang Chen, Jen-Yeu Chen, Tzu-Ting Chen, San-Yuan Huang, Jung-Sik Lee, Yuichi Saeki, Hisashi Tanaka, Tzong-Shi Wang, Bo-Jian Wu, Takao Katoh, Jun Ishigouok. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 11. issue 3. 2020-01-28. PMID:30912222. |
the efficacy and safety of lurasidone in schizophrenia has been demonstrated in multiple controlled trials, primarily in us and european populations. |
2020-01-28 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Masaomi Iyo, Jun Soo Kwon, Yuan-Hwa Chou, Hsing-Kang Chen, Jen-Yeu Chen, Tzu-Ting Chen, San-Yuan Huang, Jung-Sik Lee, Yuichi Saeki, Hisashi Tanaka, Tzong-Shi Wang, Bo-Jian Wu, Takao Katoh, Jun Ishigouok. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 11. issue 3. 2020-01-28. PMID:30912222. |
the aim of the current study was to evaluate lurasidone for the treatment of schizophrenia among patients in japan, korea, and taiwan. |
2020-01-28 |
2023-08-13 |
Not clear |